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We report here the preparation, physico-chemical characterization, and biological evaluation of a new liposome formulation as a tool for
tumor angiogenesis inhibition. Liposomes are loaded with sunitinib, a tyrosine kinase inhibitor, and decorated with cyclo-aminoprolineRGD
units (cAmpRGD), efficient and selective ligands for integrin αVβ3. The RGD units play multiple roles since they target the nanovehicles at
the integrin αVβ3-overexpressing cells (e.g. activated endothelial cells), favor their active cell internalization, providing drug accumulation in
the cytoplasm, and likely take part in the angiogenesis inhibition by interfering in the αVβ3-VEGFR2 cross-talk. Both in vitro and in vivo
studies show a better efficacy of this integrated antiangiogenic tool with respect to the free sunitinib and untargeted sunitinib-loaded
liposomes. This system could allow a lower administration of the drug and, by increasing the vector specificity, reduce side-effects in a
prolonged antiangiogenic therapy.
© 2019 Elsevier Inc. All rights reserved.
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of them being directed toward the VEGFs and their receptors
(VEGFRs).2,3 In fact, the couple VEGF-A–VEGFR2, in
particular, was recognized as the main actor in tumor
angiogenesis.4 The approved drugs are of different nature and
include monoclonal antibodies, recombinant proteins and
tyrosine kinase inhibitors (TKIs). Sunitinib, for example, is a
multi-targeted TKI, a small molecule able to hamper in particular
the phosphorylation of VEGFR2 and PDGFR, and it has been
approved as single-treatment agent for metastatic renal cell
carcinoma and pancreatic neuroendocrine tumors.5 Despite the
promises in the clinical phases, the antiangiogenic treatments
have provided only limited benefits. The reasons are several and
include: i) the lack of specific biomarkers making impossible any
selection of patients who could likely benefit from antiangio-
genic drugs; ii) the fact that most of the approved antiangiogenic
drugs are used for the treatment of advanced-stage disease, and
iii) the onset of resistance to the therapy by upregulation of other
angiogenic factors or compensatory pathways.6–8 Moreover, the
excessive blood vessel pruning causes hypoxia and can promote
cancer metastasis. For these reasons, recent approaches in the
optimization of anti-angiogenic treatments are aimed at tumor
vascular normalization, by a properly timed low dosage of anti-
VEGF or anti-VEGFR therapeutics.9–11 One of the trends
showing clinical benefits is a long-term anti-angiogenesis
therapy that can be realized only with drugs that have relatively
low toxicity and high tolerability,9 while possibly being able to
hit several pathways involved in angiogenesis at one time.
Integrins are another class of receptors that play an active role
in cancer progression and tumor angiogenesis.12–14 Integrin
αVβ3, in particular, recognizes the tripeptide sequence RGD
present in the extracellular matrix proteins, is overexpressed on
many solid tumors and activated endothelial cells during
angiogenesis and has high expression on tumor vasculature,15
potentiating the activity of tyrosine kinase receptors.16 A widely
attested cross-talk between αVβ3 and VEGFR2 enhances the
activity of both receptors and increases the VEGF-induced
angiogenesis.17–19 For these reasons, integrin αVβ3 has been
considered for years both a good tumor marker useful to target
RGD-decorated drugs or nanoparticles (NPs),20,21 and a
therapeutic target for antiangiogenic therapy15,22; however, the
recent failure of the clinical phase III of cilengitide – a potent
RGD-based ligand of integrin αVβ3 – in the cure of
glioblastoma,23 lowered the interest in this integrin subclass as
a therapeutic target.
The controversial clinical results of cilengitide and other
integrin-directed agents highlighted the complex scenario of the
actual role of integrins in cancer, due to individual variability of
their expression, activity, availability and activation states
together with the difficulty to find the right timing and dosage
in administration of an integrin inhibitor.13,24,25 Nevertheless,
according to several researchers, these difficulties should not
hamper the development of new therapeutic approaches or drugs
to target cancer-related integrins that possibly modulate multiple
yet intertwined angiogenic pathways.25
Our research group developed high-affinity αVβ3-ligands,
namely cyclic 4-aminoproline-RGD peptidomimetics
(cAmpRGD), that showed remarkable and selective bindingcapability in both cell-free and cell assays.26,27 Recently, these
cAmpRGD ligands were covalently joined to a sunitinib-like
portion, to furnish dual compounds aimed at targeting the αVβ3
integrin/VEGFR2 receptor couple, with superior antiangiogen-
esis properties as compared to the single modules (cAmpRGD
and sunitinib) or their simple combination.28 The cAmpRGD
units were also used to decorate liposomes loaded with
doxorubicine to direct the NPs at the cancer cells overexpressing
the αVβ3 integrin thus increasing the liposome uptake.
29
On the basis of these results, our goal was to develop novel
targeted cAmpRGD-liposomes loaded with sunitinib, to produce
a system capable to exploit both the passive and the active
targeting at the tumor site. Even if a liposome can extravasate
and accumulate in the tumor site because of fenestrated tumor
blood vessels and poor lymphatic drainage (enhanced perme-
ation and retention effect), the active targeting can allow the
liposome nanoparticles to overcome the high tumor interstitial
fluid pressure and reach the inner tumor layers.30 The
cAmpRGD ligands should also increase the NP internalization
via an integrin-mediated endocytosis,31 thus improving the
therapeutic index of sunitinib, and cooperate with sunitinib in the
angiogenesis inhibition. Such a system could likely allow a
spatio-temporal co-delivery of the two active units, and a lower
sunitinib administration for a more effective and tolerable
prolonged therapy.Methods
Details on materials, instrumentations, methods and experi-
mental procedures are available in the Supporting Information.
Synthesis of c(AmpRGD)-N3 2 and DSPE-PEG-RGD 3
(Figure 2) are reported in SI.
Liposome preparation and characterization
Different liposomes were prepared (see Fig. 1), namely: (a)
LN, consisting of POPC/CHOL/DSPE-PEG2000-DBCO (55/40/
5 mol/mol); (b) RGD-LN, consisting of POPC/CHOL/DSPE-
PEG-RGD (55/40/5 mol/mol); (c) PCSL-LN, consisting of
POPC/CHOL/n-PCSL/DSPE-PEG-RGD (54:40:1:5 mol/mol)
for electron paramagnetic resonance (EPR) studies; d) non-
stealth liposomes noS-LN, consisting of POPC/CHOL (60/
40 mol/mol). All the liposomes were prepared by the thin film
layer method,29 and characterized by DLS32 and ELS measure-
ments. Cryo-TEM images of RGD-LNs were taken.
Sunitinib loading
The sunitinib encapsulation was performed by exploiting an
ammonium sulfate gradient33 to obtain a 20% by mol with
respect to the lipid content. The encapsulation efficiency (EE),
defined as the percentage of drug loaded into liposomes relative
to the total amount of drug, was evaluated after ultracentrifuga-
tion procedures, through UV–Vis measurements.
Sunitinib leakage
The liposomal release of sunitinib was quantified by the
fluorescence associated to sunitinib malate upon dialysis of the
Figure 1. Compound structures and schematic representation of liposome formulations used in this work.
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medium was chosen as release medium. The change of
fluorescence intensity of the medium was monitored at different
time intervals (details in SI).
Cell lines
Endothelial progenitor cells (EPCs) were from human
umbilical cord blood samples of healthy newborns as previously
described.36
Inhibition of EPC adhesion to the αVβ3-ligand vitronectin
Suspended EPCs were treated with increasing concentrations
of the ligands, before plating them on vitronectin-coating wells.
After incubation, adherent cells were counted and the inhibitory
activity was calculated as percentage of cell adhesion to
vitronectin compared to untreated.
Inhibition of EPC growth
EPCs, seeded on gelatin-coated plates, were exposed to a
serum-free medium supplemented with 20 ng/mL VEGFA
containing sunitinib 1 μM as a free drug or in liposome
formulations, or the corresponding concentration of blank
liposomes. The number of the vital cells was determined at
24 h, 48 h, and 72 h.
Cellular uptake of sunitinib
Internalization of sunitinib was determined by flow cytometer
using the FITC channel, taking advantage of the fluorescent
emission of sunitinib.
Inhibition of VEGFR2 phosphorylation
Serum-deprived EPCs were pre-treated with sunitinib 1 μM
as a free drug or in liposome formulation for 24 h and then
stimulated with VEGFA (50 ng/mL) for 3 min. Cells were then
lysed and phosphorylated VEGFR2 on tyr951 detected.Inhibition of in vitro and in vivo angiogenesis
The effects of the different liposome formulations on the
inhibition of the capacity of EPCs to differentiate into capillary-
like network were in vitro assessed by Matrigel morphogenesis
assay, while the in vivo efficacy of these compounds was
evaluated by Matrigel sponge assay on subcutaneously im-
planted FVB mice.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD).
When appropriate, results are shown as normalized data. Data
were analyzed using analysis of variance followed by a multiple-
comparison Student–Newman–Keuls test to identify means that
are different from each other. Mean values are considered
significantly different when P b 0.05, and are indicated with
unlike letters (a, b, c, d, e, f).
All experimental procedures involving animals were per-
formed in accordance with national guidelines, approved by the
ethical committee of Animal Welfare Office of Italian Work
Ministry (401/2015PR approved 05/21/2015) and conformed to
the legal mandates and Italian guidelines for the care and
maintenance of laboratory animals.Results
Synthesis of cAmpRGD-N3 2 and phospholipid-RGD 3
The integrin ligand 2 was obtained by acidic deprotection of
the corresponding precursor, whose synthesis was previously
described28 (Scheme S1). Compound 2 was linked to the DSPE-
PEG(2000)-DBCO via an azide-alkyne Huisgen cycloaddition
reaction (click chemistry) (Figure 2). The use of the dibenzoa-
zacyclooctyne, in which the alkyne group is inserted in a highly
tensioned cycle, allows the reaction to take place very rapidly
and without the use of a Cu(I) catalytic activation or any other
salt, making the purification of the delicate phospholipid-RGD
adduct 3 very simple. The reaction was almost quantitative and
the product formation was confirmed by electrospray mass
Figure 2. (A) Synthesis of the phospholipid DSPE-PEG-RGD 3; (B) liposome preparation and sunitinib encapsulation.
Table 1
Liposome characterization.
Liposome Particle size
(nm)
Polydispersity index Zeta potential
(mV)
LN 69 ± 4 0.13 ± 0.04 −5.5 ± 0.5
LN-(sun) 65 ± 3 0.16 ± 0.06 −4.7 ± 0.6
RGD-LN 73 ± 2 0.21 ± 0.01 −5.3 ± 0.7
RGD-LN-(sun) 66 ± 3 0.25 ± 0.05 −4.5 ± 0.5
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of targeted liposomes RGD-LNs in a 5 mol% with respect to the
other constituents of the lipid bilayer.
Liposome preparation and characterization
The phospholipid-RGD 3 was co-formulated with commercial
lipids (POPC and CHOL) to obtain the targeted nano-vehicles for
sunitinib. The physicochemical investigation of the integrin-directed
liposomal nanoparticles was performed using DLS to estimate
liposome dimensions, ELS for the zeta-potential calculation and
EPR to investigate the dynamics of the lipid hydrophobic tail in the
bilayer.37 The mean hydrodynamic radii 〈RH〉 for the aqueous
dispersions of LN, LN-(sun), RGD-LN and RGD-LN-(sun)
liposome-based systems (Figure S2 and Table 1) are in the 65-
75 nm range, which is the typical range of large unilamellar vesicles.
Furthermore, a moderate polydispersity was observed for all the
aggregates, with 〈ID〉 values ranging between 0.13 and 0.25.
Membrane unilamellarity and spherical shape of these liposomes
were also confirmed by the cryo-TEM images (Figure S3). Thesurface of the blank liposomes is slightly negative (zeta-potential ~
−5.4 mV), and the sunitinib loading produces only a slight change
on the surface charge density. The EPR spectroscopy was utilized to
obtain information on the acyl chains structuring the lipid bilayers.38
EPR experiments were performed employing the spin-label
approach, analyzing spectra of phosphocholines spin-labeled on
the C5 or C14 atom of the sn-2 chain (5-PCSL and 14-PCSL,
respectively) incorporated in non-stealth liposomes (noS-LNs) and
RGD-LN liposomes. 5-PCSL bears the radical label close to the
molecule headgroup and allows the behavior of the region of the
membrane closer to the polar external layers to be monitored. In
contrast, 14-PCSLbears the radical label close to the terminalmethyl
group of the acyl chain, thus allowing the monitoring of the deep
hydrophobic core of the bilayer. In all the systems, the 5-PCSL and
14-PCSL spectra present anisotropic line-shapes (Figure S4),
indicating that the lipids are organized in a lyotropic liquid
crystalline phase more ordered than the one observed for pure
POPC.39 Effects of phospholipid-RGD 3 are weakly detectable,
indicating scarce perturbation of the bilayer structuring. This was
quantitatively confirmed by the determination of the spin-label
isotropic hyperfine coupling constant, aN’, and the order parameter,
S, which are the index of the micropolarity experienced by the
nitroxide and the index of the motion of the acyl chain segment to
which the label is bound, respectively (details in SI, Table S1).40
Sunitinib loading in lipid nanoparticles
A modified ammonium salt gradient method33 was success-
fully performed to load sunitinib into liposomes, and the
encapsulation was verified by UV–Vis spectroscopy. In the
Figure 3. (A) UV–Vis spectra of 200 μM solutions of sunitinib in PBS (black) and in RGD-LN (red). (B) Sunitinib release, expressed as %, quantified through
fluorescence upon dialysis.
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determined both in PBS and (NH4)2SO4 (see SI). Notably,
sunitinib UV–Vis spectra in ammonium salt solution show two
hallmarks: i) a blue shift of the absorbance peak; ii) a shoulder at
350 nm (Figure S5), which strongly differ from spectral features in
water and provide a reliable method to assess encapsulation of the
drugwithin the liposome. The UV–Vis spectrum of sunitinib in the
presence of liposomes with (NH4)2SO4 in the inner aqueous pool
(Figure 3, A) shows both these two features confirming the
encapsulation of sunitinib in the liposomes interior.
To estimate the encapsulation efficiency, a liposome sample
was centrifuged and the sunitinib concentration in the superna-
tant was determined by UV–Vis. Knowing the amount of
sunitinib used for encapsulation experiments, an EE% N96% w/
w was determined. Pellet deriving from this experiment was re-
suspended and stored at 4 °C in order to check the stability of the
formulation over time. No change in the liposome size
distribution (monitored by DLS) and in the UV spectrum was
observed up to two weeks.
Sunitinib leakage from lipid nanoparticles
To investigate the ability of lipid nanoparticles to maintain
sunitinib in their interior for a prolonged time, the RGD-LNs-
(sun) were put in a dialysis tube and dialyzed against DME
medium, a medium with higher viscosity than PBS that can well
mime diffusion events of sunitinib in biological assays. The
percentage of sunitinib released through diffusion mechanism
over the first 24 hours is less than 12% (Figure 3, B).
Effect of RGD-liposome formulations onEPCadhesion and viability
To evaluate the ability of the targeted liposomes (RGD-LNs) to
interact with αVβ3 integrins on the surface of endothelial cells, an
inhibition assay of adhesion of EPCs to vitronectin was performed.
The expression of αVβ3 integrins on EPCs was assessed by
cytofluorimetry to be N87% (while the expression of αVβ5 and α5β1,
other RGD-recognizing integrins, resulted negligible, Figure S7).
Blank liposomes (LNs) and the ligand cAmpRGD-NH2 were also
used. The assay was performed with increasing concentrations of
compounds in the range 0.5-5000 nM. In case of RGD-LNs, the
concentration refers to that of theRGDunits on the outer layer, whilein case of untargeted LNs it was used the same liposomal
concentration of the corresponding RGD-LNs.
The targeted RGD-LNs are able to strongly inhibit the EPC
adhesion to vitronectin even at 0.5 nM, at which concentration the
inhibition is ~50% (Figure 4, A). The comparison with the
inhibition provided by the cAmpRGD-NH2 shows a clear
multivalent effect, given by the multimeric cAmpRGD presenta-
tion on the liposomes. With cAmpRGD-NH2, 50% of inhibition is
reached at 1 μM ligand concentration, three orders of magnitude
higher than RGD-LNs. On the contrary, the untargeted liposomes
are not able to inhibit EPCs adhesion at any concentration.
The inhibition of EPCs growth insteadwas evaluated after 24 h,
48 h and 72 h incubation with the diverse liposomal formulations
or the free drug at 1 μM concentration, referred to sunitinib as free
drug or encapsulated in the liposome. Blank liposomes were used
at the same concentration of the loaded liposomes. Both LNs and
RGD-LNs are not cytotoxic and do not inhibit the cell growth,
confirming the biocompatibility of the targeted RGD-LNs as
nanovehicles. The loaded targeted liposomes RGD-LN-(sun)
showed an inhibitory effect comparable to that of free sunitinib
at 24 h, but stronger at 48 h and 72 h. Moreover, the activity of
RGD-LN-(sun) is superior to that of LN-(sun), and this is likely
due to an active role of cAmpRGDunits in the internalization of the
nanoparticles. In fact, since the corresponding blank formulation
RGD-LN has no influence on the cell growth, the stronger
inhibition by RGD-LN-(sun) can be explained only with a higher
intracellular concentration of sunitinib (Figure 4, B).Cell uptake of sunitinib
The internalization of sunitinib in EPCs was assessed through
immunofluorescence analysis and flow cytometry measurements,
analyzing the cellular fluorescence intensity (λexc = 429 nm and
λem = 540 nm). The cell uptake of targeted liposomes was
investigated using fluorescence confocal microscopy after exposure
to free sunitinib (10 μM), LNs-(sun) or RGD-LNs-(sun) containing
10 μM of sunitinib. The treatment lasted 3 h, to allow a significant
cellular internalization without compromising cell viability. The
nuclei were stained with DAPI. Cells exposed to RGD-LNs-(sun)
showed an intense and diffuse fluorescence, higher than the one
observed for cells incubated with free sunitinib or with LNs-(sun).
Figure 4. (A) Inhibition of EPCs adhesion to vitronectin expressed as mean value ± SD of at least three independent experiments. (B) Inhibition of EPCs growth
after treatment with sunitinib 1 μM, or different liposome formulations. Histograms refer to mean ± SD (n = 3) of the number of viable cells after 24 h, 48 h, 72
h of treatment. Unlike letters (a, b, c, d, e, f) indicate significantly different means P b 0.05 (see Statistical Analysis).
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ed in intracellular vesicles only when given as free drug (Figure 5,
A). To further confirm the more efficient intracellular uptake of
RGD-LNs-(sun) compared to sunitinib or LNs-(sun), a prolonged
treatment at 1 μMconcentration was performed and evaluated using
cytofluorimetric assay (Figure 5, B). The percentages of cellular
populations showing a fluorescence intensity higher than the
threshold value (cellular autofluorescence) are reported. Higher
percentages mean higher intracellular sunitinib concentration (blank
liposomes do not impact the overall cell autofluorescence, Figure
S8). The data show that the targeted liposomes facilitate the uptake of
sunitinib in comparison to both the untargeted liposomes and to the
free drug. The gain in the sunitinib uptake by RGD-LNs-(sun) is
more marked at shorter times (24 h and 48 h), when a noticeably
amount of fluorescent cells was measured. Instead, after 72 h
exposition, the percentages of fluorescent cells for the two liposomes
were similar but still higher than that of free sunitinib.
Effect of RGD-liposome formulations on VEGFR2 phosphorylation
and in vitro tubulogenesis
In order to evaluate whether the VEGFR2 inhibiting activity
of sunitinib is maintained even when administered by a liposomeformulation, or it is even risen because of a concurrent inhibition
of integrin αVβ3, a VEGFR2 phosphorylation assay was
performed. The ability of sunitinib 1 μM as either free drug or
in targeted RGD-LN-(sun) and untargeted LN-(sun) liposomes to
inhibit VEGF-stimulated VEGFR2 phosphorylation was inves-
tigated by Western blotting using EPCs. Percent inhibition is
reported in the densitometric analysis histogram (Figure 6, A).
EPCs were treated for 24 h with the different compounds/
formulations and then activated with 50 ng/mL VEGF-A for
3 min, before cell lysis for VEGFR2 phosphorylation detection.
As expected, sunitinib strongly inhibits the VEGFR2 phosphor-
ylation when administered both as a free drug and in liposome
formulations. The best inhibition effect was obtained with the
targeted liposomes, RGD-LN-(sun), and this can be correlated
with their superior ability to be internalized. LNs-(sun) strongly
inhibit VEGFR2 phosphorylation, but less efficiently than RGD-
LNs-(sun), in a manner comparable to that of free sunitinib. This
evidence is still in line with the amount of sunitinib cell uptake
measured by cytofluorimetric analysis.
To further investigate the anti-angiogenic effect of the
sunitinib-loaded liposomes, we evaluated the in vitro tube
formation of EPCs seeded on Matrigel (Corning). Cells were
exposed to a medium containing VEGF-A (20 ng/mL) and
Figure 5. Immunofluorescence assay of EPCs treated for 3 h with free sunitinib 10 μM, LN-(sun) or RGD-LN-(sun) at 10 μM (A) and cytofluorimetric assay of
EPCs treated daily for up to 72 h (B) with free sunitinib 1 μM, LN-(sun) or RGD-LN-(sun) at 1 μM. Representative images of at least three independent
experiments.
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at 1 μM concentration of sunitinib. The anti-angiogenic activity
was compared to that of free sunitinib 1 μM, cAmpRGD-NH2 at
0.15 μM, and to the co-administration of sunitinib (1 μM) and
cAmpRGD-NH2 (0.15 μM). The choice of using cAmpRGD-NH2
at 0.15 μM is due to the fixed ratio [sunitinib]/[RGD] in the
liposome formulation, that is 1/0.15, hence the necessity of using
the same concentration of the active ingredients (RGDor sunitinib)
to compare their biological effects either as free drugs or within the
liposome formulations. The antiangiogenic effect was reported as
inhibition of capillary network formation (Figure 6, B, upper
panel), given by the lower number of loops formed by connecting
capillary projections (branches) with respect to the control
experiment (Figure 6, B, lower panel).
The best in vitro inhibition of the capillary formation was
given by the RGD-LNs-(sun) that, when administered at 1 μM
sunitinib concentration, were able to induce a 70% inhibition. In
this experiment, the different activity of targeted and untargeted
liposomes is evident. Interestingly, sunitinib as a free drug is
markedly less effective with respect to the liposomal formula-
tions, and this result can be ascribed to a lower cell uptake
(Figure 5). cAmpRGD-NH2 at low concentration (0.15 μM) has
a very slight antiangiogenic activity. Finally, a combinedtreatment of free sunitinib and cAmpRGD-NH2 was examined
and the synergy of the two active units in the antiangiogenic
activity was confirmed by an inhibition percentage higher than
the sum of the single treatments.In vivo inhibition of angiogenesis
Since the targeting effect of the RGD cannot be appreciated
using in vitro assays, where the drug is added into the wells in
direct contact with the cells, the in vivo anti-angiogenesis
evaluation was performed, using a mice-implanted Matrigel plug
assay. The ability of targeted RGD-LNs-(sun) to block
angiogenesis was compared to that of the untargeted liposomes
LNs-(sun) and sunitinib alone (as a malate salt). Matrigel
sponges were subcutaneously injected into the flanks of nude
mice, and compounds were daily intraperitoneally administered,
with the aim to better appreciate the targeting effect of the RGD
units. Plugs were removed from mice after 4 days of treatments
and photographed. Despite the preliminary character of the data,
a qualitative picture of the activity of the compounds was
obtained (Figure 7). While the sponges recovered by untreated
mice are crossed by a clear and evident blood vessel network, the
sponges from treated mice show the effect of the antiangiogenic
Figure 6. (A) Inhibition of VEGFR2 phosphorylation in EPCs treated with 1 μM concentration of sunitinib, or different liposome formulations. Data are
expressed as densitometric analysis compared to untreated cells and normalized to β-actin expression of three independent experiments (upper panel).
Representative immunoblots (lower panel). (B) Inhibition of in vitro tubulogenesis of EPCs incubated for 18 h with cAmpRGD-NH2 (0.15 μM), sunitinib
(1 μM), cAmpRGD-NH2 (0.15 μM) + sunitinib (1 μM), LN-(sun) (1 μM referred to sunitinib) and RGD-LN-(sun) (1 μM referred to sunitinib). Histograms
refer to mean ± SD (three independent experiments) of the inhibition of branches development in three different fields as compared to untreated cells and
expressed as percentage (upper panel). Representative images of the different treatments (lower panel). Unlike letters (a, b, c, d, e, f) indicate significantly
different means P b 0.05 (see Statistical Analysis).
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administered, only some tiny capillaries formed. Targeted
liposomes RGD-LNs-(sun) gave an even better inhibition, in
fact capillaries are pretty much absent in the plug. Noteworthy,
the Matrigel plugs of mice treated with liposome formulations
exhibit an intense yellow coloring, meaning high accumulation
of sunitinib. This is observed also with the untargeted liposomes,
suggesting that the liposome formulation itself could favor the
accumulation in the Matrigel plug, when the leaky capillary
network is insufficient to support drug clearance.Discussion
The goal of this work was to develop targeted liposomes loaded
with sunitinib for a potentiated inhibition of tumor angiogenesis by a
spatio-temporal co-administration of sunitinib and an αVβ3
antagonist. The cAmpRGD targeting units on the liposome surface
should exert three main functions: i) to actively deliver the
nanoparticle to the tumor site, ii) to increase the receptor-mediated
cell uptake of liposomes and iii) to interfere in the αVβ3-VEGFR2
cross-talk of angiogenic signal. Most of the literature examples of
Figure 7. Inhibition of in vivo angiogenesis in Matrigel plugs implanted in FVB mice. Matrigel plugs contained VEGF-A/heparin. A daily IP administration of
PBS (ctrl), 10 mg/kg of sunitinib or equivalent quantity within LN-(sun) or RGD-LN-(sun) was carried out. Plugs were removed from mice and photographed
after 4 days (in the second line magnifications of the plugs above are reported).
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cytotoxic drug, such as doxorubicin or paclitaxel, to damage
activated endothelial cells,42,43 while the attempts to target a TKI for
an angiogenic signal modulation are rare.44 The few examples of
sunitinib liposomes were developed in combination with a cytotoxic
drug to combine the antitumor and antiangiogenic activity; sunitinib
was co-loadedwith irinotecan in the same untargeted liposome,45 or,
more recently, sunitinib-loaded liposomes and vironelbine lipo-
somes were co-administered to treat invasive breast cancer.46 To
best of our knowledge, however, this is the first example of targeted
RGD-liposomes loaded with sunitinib.
Theplasma stability of the targetingunit cAmpRGD, a prerequisite
for in vivo applications,was previously investigated27,28; its structural
integrity was completely preserved under treatment in either
human or rat plasma for 6-8 h. The DSPE-PEG-RGD 3 was used
in the formulation of the targeted liposomes at a concentration of
5%mol/mol with respect to the total amount of phospholipids. The
lipid bilayer was formed by POPC (55%mol/mol) and cholesterol
(40% mol/mol). POPC was chosen being probably the most
diffused lipid in eukaryotic cells, while CHOL was added to
rigidify the membrane and minimize the sunitinib leakage. The
internal core was acidic thanks to 300 mM concentration of
(NH4)2SO4 used as trapping agent. It has to be highlighted that
both a rigid membrane and (NH4)2SO4-enriched liposome interior
were necessary for a stable encapsulation of sunitinib.
The liposomal formulation developed in this work presents
suitable physicochemical characteristics for in vivo application.
The average RH of ~70 nm has been reported to be suitable for a
preferred tumor accumulation via the EPR effect, with the
consequence of a reduced uptake of sunitinib in healthy organs.
The 5% of PEG2000 lipid derivatives ensures longer circulation
time by preventing opsonization through the induction of a fixed
aqueous layer on the liposome surface. The length of PEG2000
chain, present in the formulation at percentages in the range 5-
9.6% mol/mol, was reported to be optimal to ensure in vivo
stealth properties of targeted liposomes.47The purposely designed liposomes, through the optimized
loading protocol, were able to encapsulate more than 95% of
sunitinib present in the loading medium. Once encapsulated in
the liposome inner aqueous pool, sunitinib is hardly released, as
demonstrated by the leakage experiments, so that liposomes can
be thought to safely carry the drug in the treated organism.
For the in vitro studies, the bone marrow-derived endothelial
progenitor cells (EPCs) were used. In fact, EPCs are involved in
tumor angiogenesis48,49 and it was reported that the levels of
circulating EPCs are correlatedwith themalignancy of certain tumors
in human patients.50,51 These cells overexpress theαVβ3 integrins and
they upregulate the VEGFR2 expression when exposed to VEGF.52
The binding inhibition of EPCs to vitronectin was measured
to assess the interaction between the RGD-liposomes and αVβ3
receptors. The assay showed a strong adhesion inhibition of
EPCs to vitronectin by the targeted liposomes (Figure 4, A), with
an IC50 in the order of 1 nM, 1000 times lower than the IC50
measured with the reference monomer compound cAmpRGD-
NH2, revealing a clear multivalent effect of the multimeric
presentation of RGD motifs on RGD-LNs. Conversely, the
untargeted liposomes LNs did not show any ability to interact
with the αVβ3 integrin, confirming that the adhesion inhibition
registered with RGD-LNs was acted only by the RGD units and
not due to the liposome structure.
In order to evaluate whether higher integrin binding caused
higher internalization, the cell fluorescence was measured by
flow cytometry and correlated to the intracellular sunitinib
concentration. Free sunitinib can easily pass through the cell
membrane and accumulate in the cytoplasm.28 After 24 h,
however, the amount of sunitinib internalized in EPCs was
significantly higher when administered loaded in targeted RGD-
LNs. Targeted liposomes facilitate the sunitinib uptake with
respect to the untargeted liposomes as well, likely via a receptor-
mediated endocytosis. This conclusion was also supported by the
cell growth inhibition experiments (Figure 4, B). In fact the
blank liposomes LNs and RGD-LNs did not interfere in the cell
144 F. Bianchini et al / Nanomedicine: Nanotechnology, Biology, and Medicine 18 (2019) 135–145growth, demonstrating the total safety of the nanocarriers
proposed in this study, while the targeted RGD-LNs-(sun) had
an inhibitory effect markedly higher than both the untargeted
liposome LNs-(sun) and free sunitinib, results in line with the
increased cell uptake of sunitinib.
Sunitinib loaded in liposomes is still able to work as a TKI
inhibitor, meaning that it can escape the endosomes through
which the RGD-LNs are presumably internalized and go to
inhibit the VEGFR2 phosphorylation (Figure 6, A). Again,
RGD-LNs-(sun) revealed to be the best formulation to maximize
the sunitinib activity. Surprisingly, the cAmpRGD-NH2 in-
creased the VEGFR2 phosphorylation. We can postulate that the
binding of the RGD-antagonist to αVβ3 integrin, at this
concentration, causes a rapid phosphorylation of the VEGFR2
as compensatory mechanism.
To further investigate the effect of the targeted RGD-LNs-
(sun) on angiogenesis we evaluated, in vitro, the ability of EPCs
to develop capillary network on a Matrigel-coated substratum
and, in vivo, the ability of mice-resident endothelial cells to
produce vessels in Matrigel plug assay. Tube-forming assays, in
fact, offer an excellent overview of the molecular processes in
angiogenesis, and can furnish an indication of the behavior of the
inhibitors on the dynamic process of formation of new blood
vessels. The in vitro assay showed that both LNs-(sun) and
RGD-LNs-(sun) were able to efficiently inhibit the VEGF-A
activated angiogenesis even though with a different efficiency
(Figure 6, B), and both were sensibly more active than free
sunitinib (~70% and 52% inhibition vs 32%). The superiority of
RGD-LNs-(sun) with respect to LNs-(sun) can also be due to a
contribution of RGD units in αVβ3/VEGFR2 cross-talk inhibi-
tion. Lastly, the RGD-LNs-(sun) were definitely more efficient
than the untargeted LNs-(sun) also in in vivo experiment, being
able to inhibit completely the formation of new blood vessels. It
is to be noted that the in vivo treatments were carried out at a sub-
optimal dose of sunitinib, showing that the targeted liposomes
can allow the concentration of the administered drug to be
decreased.
Thus, the RGD-decorated liposomes demonstrated to be a
selective agent for antiangiogenic treatment. The combined action
of cAmpRGD and sunitinib in the inhibition of αVβ3 integrin and
VEGFR2 and their cross-talk can be plausibly invocated, even if
not unequivocally demonstrated. The key roles of the multiple
cAmpRGD units in both targeting sunitinib-loaded liposomes and
favoring their cell internalization are evident.Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.nano.2019.02.015.
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